tradingkey.logo
tradingkey.logo
Search

Lyell Immunopharma Inc

LYEL
Add to Watchlist
14.300USD
-1.340-8.57%
Close 11-13 16:00(ET)
350.49MMarket Cap
LossP/E TTM

LYEL Financials

See Lyell Immunopharma Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.
Key Financial Ratios
Market Cap
350.49M
Dividend TTM
0.00
P/E TTM
-1.05
EPS TTM
-13.62
Revenue
36.00K
Net Profit
-342.99M
ROE
-80.76%
ROA
-63.15%
Lyell Immunopharma Inc Earnings Date
Latest Release
Nov 4, 2026
EPS / Forecast
-1.86/-2.07
Revenue / Forecast
3.00K/2.33K

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q3
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
Financial Indicators
EPS
12.38%-1.86
33.61%-1.92
68.79%-1.10
49.98%-6.86
38.87%-2.13
19.56%-2.89
25.87%-3.54
-227.46%-13.71
14.04%-3.48
29.76%-3.59
11.06%-4.77
-546.80%-4.19
---4.05
---5.11
---5.37
---0.65
---0.71
----
----
----
Revenue
-80.00%3.00K
-50.00%4.00K
-71.43%2.00K
-45.45%6.00K
-55.88%15.00K
-38.46%8.00K
133.33%7.00K
-15.38%11.00K
36.00%34.00K
-51.85%13.00K
-95.38%3.00K
-99.97%13.00K
733.33%25.00K
-99.92%27.00K
-88.25%65.00K
1614.60%48.39M
-99.89%3.00K
1260.01%35.74M
-77.38%553.00K
22.06%2.82M
Net Profit
-17.20%-45.53M
-4.85%-44.76M
53.73%-24.15M
26.68%-140.72M
12.87%-38.85M
6.82%-42.68M
13.96%-52.20M
-262.62%-191.94M
12.33%-44.58M
28.30%-45.81M
9.40%-60.67M
-530.34%-52.93M
27.62%-50.85M
-75.89%-63.89M
1.74%-66.96M
89.97%-8.40M
-43.74%-70.25M
41.97%-36.32M
-23.80%-68.14M
-115.42%-83.71M
Net Margin
-486.02%-1517633.33%
-109.70%-1118875.00%
-61.96%-1207650.00%
-34.42%-2345383.33%
-97.50%-258973.33%
-51.41%-533550.00%
63.13%-745642.86%
-328.55%-1744863.64%
35.54%-131126.47%
-48.91%-352376.92%
-1863.07%-2022233.33%
-2346041.46%-407153.85%
---203412.00%
---236629.63%
---103013.85%
---17.35%
---481.36%
----
----
----
Gross Margin
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
0.00%100.00%
--100.00%
--100.00%
--100.00%
--100.00%
--100.00%
----
----
----
Debt to assets ratio
----
----
----
----
----
----
----
----
----
----
----
--0.00%
--0.00%
--0.00%
--0.00%
--0.00%
--0.00%
----
----
----
Revenue
-80.00%3.00K
-50.00%4.00K
-71.43%2.00K
-45.45%6.00K
-55.88%15.00K
-38.46%8.00K
133.33%7.00K
-15.38%11.00K
36.00%34.00K
-51.85%13.00K
-95.38%3.00K
-99.97%13.00K
733.33%25.00K
-99.92%27.00K
-88.25%65.00K
1614.60%48.39M
-99.89%3.00K
1260.01%35.74M
-77.38%553.00K
22.06%2.82M
Operating profit
-29.64%-48.30M
-6.05%-47.34M
23.01%-44.26M
2.93%-61.31M
28.00%-37.25M
15.67%-44.75M
-5.28%-57.49M
-1.40%-63.16M
12.36%-51.74M
19.48%-53.06M
15.03%-54.61M
-181.96%-62.29M
7.75%-59.04M
-95.71%-65.91M
11.27%-64.26M
53.53%-22.09M
-30.18%-64.00M
46.30%-33.67M
-30.81%-72.43M
-20.28%-47.54M
Net Profit
-17.20%-45.53M
-4.85%-44.76M
53.73%-24.15M
26.68%-140.72M
12.87%-38.85M
6.82%-42.68M
13.96%-52.20M
-262.62%-191.94M
12.33%-44.58M
28.30%-45.81M
9.40%-60.67M
-530.34%-52.93M
27.62%-50.85M
-75.89%-63.89M
1.74%-66.96M
89.97%-8.40M
-43.74%-70.25M
41.97%-36.32M
-23.80%-68.14M
-115.42%-83.71M
Current assets
-43.26%186.21M
-24.33%213.54M
-13.54%267.30M
-31.26%260.94M
-27.07%328.20M
-43.54%282.21M
-42.12%309.18M
-31.57%379.59M
-23.31%450.05M
-17.58%499.82M
-14.45%534.16M
-14.83%554.69M
-11.05%586.85M
-9.05%606.41M
-0.21%624.40M
3.99%651.29M
4.53%659.75M
-20.13%666.78M
2.62%625.71M
--626.29M
Total current liabilities
45.15%46.27M
8.03%39.87M
-10.51%36.95M
-8.14%49.41M
-4.88%31.88M
19.51%36.90M
27.61%41.28M
55.82%53.79M
-4.43%33.51M
-10.21%30.88M
5.05%32.35M
-6.78%34.52M
-31.54%35.06M
-31.62%34.39M
-24.99%30.80M
-20.78%37.03M
-13.60%51.22M
-21.00%50.29M
-27.74%41.05M
--46.74M
Total assets
-32.87%273.85M
-19.28%311.15M
-18.42%350.63M
-30.72%340.05M
-34.12%407.96M
-41.08%385.45M
-38.09%429.80M
-34.55%490.86M
-22.11%619.22M
-21.69%654.14M
-21.15%694.22M
-20.00%750.03M
-18.65%794.99M
-18.24%835.35M
-17.88%880.45M
-16.84%937.56M
-18.45%977.27M
-16.93%1.02B
22.22%1.07B
--1.13B
Total liabilities
2.90%81.13M
-10.62%77.34M
-17.49%76.96M
-14.98%91.85M
-10.93%78.84M
-1.27%86.53M
2.43%93.28M
13.63%108.03M
-9.13%88.52M
-11.02%87.64M
-5.76%91.06M
-8.85%95.08M
-38.05%97.42M
-35.89%98.50M
-49.37%96.62M
-47.22%104.31M
-25.78%157.24M
-26.11%153.63M
-4.70%190.85M
--197.62M
Total equity
-41.44%192.72M
-21.78%233.81M
-18.68%273.67M
-35.17%248.20M
-37.98%329.12M
-47.23%298.92M
-44.21%336.52M
-41.55%382.82M
-23.92%530.70M
-23.12%566.50M
-23.05%603.16M
-21.40%654.95M
-14.93%697.57M
-15.11%736.86M
-11.06%783.83M
-10.38%833.25M
-16.87%820.03M
-15.06%868.04M
30.19%881.25M
--929.79M
Net operating income
-20.96%-34.57M
1.56%-33.92M
29.65%-38.51M
31.73%-32.25M
18.45%-28.58M
9.54%-34.46M
-30.28%-54.74M
-16.26%-47.24M
7.02%-35.04M
2.72%-38.09M
9.08%-42.02M
-0.91%-40.63M
-1.57%-37.69M
11.67%-39.16M
3.43%-46.21M
-21.38%-40.27M
-45.55%-37.10M
-30.59%-44.33M
-42.43%-47.85M
-24.09%-33.17M
Net investment
1500.30%53.59M
23.48%15.62M
-74.98%17.38M
-158.62%-31.36M
74.61%3.35M
-71.90%12.65M
215.84%69.47M
153.14%53.51M
-98.08%1.92M
-70.57%45.01M
-31.60%21.99M
-315.85%-100.69M
274.60%99.67M
511.18%152.91M
223.09%32.15M
163.12%46.65M
60.61%-57.09M
163.38%25.02M
-119.11%-26.12M
-328.18%-73.90M
Net financing
-99.92%41.00K
185.25%522.00K
5172100.00%51.72M
-49.20%222.00K
--50.00M
-78.77%183.00K
-96.30%1.00K
-42.42%437.00K
100.00%0.00
-27.93%862.00K
139.13%27.00K
-12.05%759.00K
-103.00%-143.00K
-51.32%1.20M
-102.70%-69.00K
-88.34%863.00K
996.42%4.76M
-99.38%2.46M
189.03%2.56M
2089.05%7.40M

FAQs

What is the total revenue of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its total revenue reached 36.00K, with a year-on-year change of 61.00K.

What are the current assets of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its current assets were 260.94M, with a year-on-year change of -31.26.

What are the total assets of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its total assets of Lyell Immunopharma Inc were 340.05M, with a year-on-year change of -30.72.

What are the total liabilities of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its total liabilities of Lyell Immunopharma Inc were 91.85M, with a year-on-year change of -14.98.

What is the total equity of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its total equity of Lyell Immunopharma Inc was 248.20M, with a year-on-year change of -35.17.

What is the net operating income of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its net operating income of Lyell Immunopharma Inc was -201.63M, with a year-on-year change of 8.95.

What is the net investment of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its net investment of Lyell Immunopharma Inc was 54.10M, with a year-on-year change of -55.81.

What is the net financing of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its net financing of Lyell Immunopharma Inc was 50.41M, with a year-on-year change of 3701.36.

What is the Earnings Per Share (EPS) of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -16.06, with a year-on-year change of 38.80.

What is the net income of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its net income was -274.45M, with a year-on-year change of 19.98.

What is the net margin of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its net profit margin was -762355.56, with a year-on-year change of -35.58.

What is the Return on Equity (ROE) of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its Return on Equity (ROE) was -86.98, with a year-on-year change of -31.59.

What is the Return on Assets (ROA) of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its Return on Assets (ROA) was -66.06, with a year-on-year change of -19.50.

What is the operating profit of Lyell Immunopharma Inc?

According to Lyell Immunopharma Inc's FY2025 earnings report, its operating profit was -201.63M, with a year-on-year change of 8.95.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.